Therefore, the insulinotropic, glucoregulatory and anorectic actions of GIP and GLP-1 have supported the development of incretin-based therapies for the treatment of T2D and obesity [1]. This evidence concerns the gene GIP and obesity due to melanocortin 4 receptor deficiency.